| Texto completo | |
| Autor(es): |
de Souza, Marcela
[1, 2]
;
Matsuzawa, Tetsuhiro
[3]
;
Lyra, Luzia
[4]
;
Busso-Lopes, Ariane Fidelis
[1]
;
Gonoi, Tohru
[3]
;
Schreiber, Angelica Zaninele
[4]
;
Kamei, Katsuhiko
[3]
;
Moretti, Maria Luiza
[1]
;
Trabasso, Plinio
[1]
Número total de Autores: 9
|
| Afiliação do(s) autor(es): | [1] Univ Estadual Campinas, Sch Med, Dept Internal Med, Campinas, SP - Brazil
[2] HC FMUSP, Parasitol Lab, LIM 46, Sao Paulo - Brazil
[3] Chiba Univ, Med Mycol Res Ctr, Chiba - Japan
[4] Univ Estadual Campinas, Sch Med, Dept Clin Pathol, Campinas, SP - Brazil
Número total de Afiliações: 4
|
| Tipo de documento: | Artigo Científico |
| Fonte: | SPRINGERPLUS; v. 3, AUG 30 2014. |
| Citações Web of Science: | 9 |
| Resumo | |
Introduction: During the last decades, Fusarium spp. has been reported as a significant cause of disease in humans, especially in immunocompromised patients, who have high risk of invasive life-threatening disease. Fusarium species usually reported as cause of human disease are F. solani, F. oxysporum and F. verticillioides. Case description: We describe the second case in the literature of disseminated fusariosis caused by Fusarium napiforme, that occurred in a 60-year-old woman with multiple myeloma after subsequent cycles of chemotherapy. Discussion and Evaluation: We identified the F. napiforme not only by standard morphologic criteria by macroscopic and microscopic characteristics, but also confirmed by molecular biology methods, including sequencing. The antifungal susceptibility of the F. napiforme isolates were tested to seven antifungal drugs; the azoles were the most active drug against all the isolates tested. Conclusions: Fusarium spp. are of relevance in medical mycology, and their profiles of low susceptibility to antifungal drugs highlight the importance for faster and more accurate diagnostic tests, what can contribute to an earlier and precise diagnosis and treatment. (AU) | |
| Processo FAPESP: | 11/16205-5 - Identificação das espécies de Fusarium de amostras clínicas do Hospital de Clínicas da UNICAMP através das técnicas de Microarranjo de DNA e amplificação isotérmica em ciclos (LAMP). |
| Beneficiário: | Marcela de Souza |
| Modalidade de apoio: | Bolsas no Brasil - Mestrado |